Stanley Laman Group Ltd. Purchases 3,262 Shares of Amgen Inc. (NASDAQ:AMGN)

Stanley Laman Group Ltd. lifted its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 32.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,215 shares of the medical research company's stock after buying an additional 3,262 shares during the quarter. Stanley Laman Group Ltd.'s holdings in Amgen were worth $4,117,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Centricity Wealth Management LLC acquired a new position in shares of Amgen during the fourth quarter worth approximately $25,000. Pinney & Scofield Inc. acquired a new position in shares of Amgen during the fourth quarter worth about $26,000. Ritter Daniher Financial Advisory LLC DE lifted its position in Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after buying an additional 51 shares in the last quarter. Synergy Investment Management LLC acquired a new position in Amgen during the fourth quarter worth $34,000. Finally, Atala Financial Inc acquired a new stake in Amgen in the 4th quarter valued at about $34,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on AMGN shares. Wall Street Zen raised shares of Amgen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 18th. Piper Sandler lowered their price target on shares of Amgen from $329.00 to $328.00 and set an "overweight" rating on the stock in a report on Friday, May 16th. Morgan Stanley restated an "equal weight" rating on shares of Amgen in a report on Friday, May 2nd. Cantor Fitzgerald initiated coverage on Amgen in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $305.00 target price on the stock. Finally, Johnson Rice set a $294.00 price objective on shares of Amgen in a research note on Wednesday, March 5th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $309.22.

Amgen Trading Down 0.7%

NASDAQ:AMGN traded down $2.07 during trading hours on Friday, hitting $295.22. 2,191,182 shares of the company were exchanged, compared to its average volume of 2,816,229. The company has a fifty day simple moving average of $281.03 and a 200 day simple moving average of $285.48. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The stock has a market capitalization of $158.74 billion, a price-to-earnings ratio of 39.10, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.72. The business had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Amgen's revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.96 earnings per share. Sell-side analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Insider Activity

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the firm's stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the transaction, the senior vice president now directly owns 8,162 shares of the company's stock, valued at $2,364,368.16. This trade represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.76% of the company's stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.